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ABSTRACT: The resistance patterns of 100 local strains of Ps. aeruginosa were investigated using 
two different methods: (1) Broth Dilution and (2) £-test. From the seven antibiotics tested, Ps. 
aeruginosa showed a 100% sensitivity to imipenem (n=30). Among the first-line agents, azlocillin, 
ceftazidime, and gentamicin showed the highest sensitivity rates, 87%, 93% and 92%, respectively. 
Aztreonam and ciprofloxacin showed the presence of intermediately sensitive strains, with 61 % of 
the isolates tested being fully sensitive to each antibiotic. Only 47% of the strains were found to be 
sensitive to ceftriaxone. The results obtained were similar to studies carried out abroad. 
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Introduction 
Ps. aeruginosa can colonise healthy individuals as a 
harmless saprophyte. It is known to be a major cause of 
nosocomial infections particularly as it grows virtually 
everywhere including respirators used in operating 
theatres. It is one of the most important hospital 
pathogens especially in patients with a degree of 
immunosuppression. It is important because many 
strains show a degree of multiple drug resistance. The 
degree of resistance to several antibiotics among clinical 
isolates of Ps. aeruginosa has been increasing in recent 
years. 
Bronchopneumonia, septicaemia, meningItIS, and 
urinary tract infections caused by Ps. aeruginosa may 
be acute or chronic in relation to the host immune 
reactivity. Ps. aeruginosa is also a cause of severe 
epidemic diarrhoea in infants, ocular and bum infections, 
osteomyelitis and malignant external otitis. 
The pathology of a Ps. aeruginosa infection includes 
necrosis and haemorrhagic lesions, infiltration by 
mononuclear cells, cytotoxic effects on macro phages and 
polymorphonuclear leukocytes, and widespread 
granulomatous lesions. 
According to the National Nosocomial Infections 
Surveillance System (NNIS), Ps. aeruginosa is the third 
most important nosocomial pathogen (11 %) I. 
Methods 
The samples used in this study were taken from 
clinical isolates which were identified as Ps. aeruginosa 
by the laboratory staff as part of their routine work. 
(1) The Broth Dilution Technique 
Iso-Sensitest Broth® was used for this method. Each 
sample that did not show growth was inoculated on 
Blood Agar to determine whether a particular 
concentration was inhibitory or bactericidal. The lowest 
concentration (i.e., highest dilution) which did not show 
growth on the agar plate was the MBC. By determining 
both MIC and MBC tolerance was also estimated. 
Tolerance is of the utmost importance in cases where 
bactericidal therapy is a requirement. 
(2) £-Test technique 
Half the plate was swabbed with the control strain 
(ATCC 27853), the other half being inoculated with the 
test strain so that in using this procedure each £-test strip 
had a simultaneous control run2. 
£-Test MIC values have been shown to be reproducible 
and directly proportional to MIC values from the 
NCCLS reference agar dilution procedure3. 
Results 
The MIC50 and MIC90 data together with the MIC 
range for the seven antibiotics tested are shown in Table 
l. 
Figure 1 shows the qualitative classification of the data 
obtained. Isolates are classified as Sensitive, 
Intermediate or Resistant to the respective antibiotic. The 
breakpoints followed were those recommended by the 
European Committee for Clinical Laboratory Standards 
(ECCLS). 
Tolerance 
Tolerance is when the MIC/MBC ratio is 32 (i.e. the 
difference between MIC and MBC is ~ 6 two-fold 
dilution factors. A high frequency of tolerance was 
found with azlocillin, as illustrated in Figure 2. 
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Table 1 - In vitro activity of antibacterial agents against Ps. aeruginosa. 
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Antimicrobial MIC50 MIC90 Mean MIC MIC range Breakpoints Percent 

Agent (f.1g/ml) (f.1g/ml) (f.1g/ml) (f.1g/ml) Susceptible 

Azlocillin 4 128 13.64 <8 - >256 S= <64 R= >128 87 

Aztreonam 8 32 6.68 <2 i >64 s= <8 R= >32 81 

Ceftazidime 2 8 3.03 <2 - >64 S= <16 R= >32 97 

Ceftriaxone 64 64 24.06 2 - >32 s= <16 R= >32 47 

Ciprofloxacin 1 16 1.04 <0.25 - >8 S= <1 R= >4 79 

Gentamicin 2 8 2.69 <1 - >32 S= <4 R= >8 92 

Imipenem 1 2 1.17 0.25 - 4 S= <4 R= >16 100 

Fig. 1 - Qualitative Results 
Multiple Drug Resistance 
Multiple Drug Resistance (MDR) is yet another 
distressing problem. Figure 3 shows the resistance 
patterns of the 100 isolates studied. All the strains were 
fully sensitive to imipenem. 
The criterion chosen for defining Multiple Drug 
Resistance was that an isolate results resistant to two or 
more antimicrobial agents excluding ceftriaxone which 
is not an antipseudomonal cephalosporin. Thus a total of 
14 isolates were classified as MDR. Figure 3 shows the 
resistance patterns of the 100 isolates studied. 
Comparison with other studies 
Table 2 summarises the comparison of results obtained cQ) Q) c E@ E c '0 '0 Q)C1l E c 	 in this study with studies carried out abroad. The results '0 c 0 C1l Q)'5 x 'E 0 0 x 
N 'N C1l 0 C1l a. 	 obtained in different studies follow the same trend in C1l c;::C1l ~ .t:: ~ e i: Q) :§ 	 resistance and any differences in results are mainly due Q) Q)C1l Cl() () a. 
'0 	 to geographical variation in resistance patterns. The only 
relevant difference is , with ciprofloxacin to which 
Maltese strains show higher levels of resistance. sensitivity 
Discussion 
ToleranceFig. 2 - Tolerance If a species has high resistance to an antibiotic (e.g., 
ceftriaxone, Figure 1), this can be detected by routine 
Fig. 3 - Multiple Drug Resistance 
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Table 2. Comparison with other studies. 
Antibiotic 	 Sensitivity (%) Nation Author and year 
Malta Abroad 
Azlocillin 87 62 Germany Ansorg. et al. . 19904 
Aztreonam 81 78.3 Multicentre study Verbist. 19945 
88.0 Germany Abb.19926 
90.4 Greece Sofianu. et al . 19897 
Ceftazidime 97 91.7 Multicentre srudy Verbist. 19945 
93.0 Germany Abb. 19926 
82 Germany Ansorg. et al.. 19904 
93.0 Greece Sofianu. et al, 19897 
Ceftriaxone 47 <50 Germany Ansorg. et al.. 19904 
62.0 Greece Sofianu. et al.. 19897 
Ciprofloxacin 79 90.0 Germany Abb.19926 
90 Germany Ansorg. et a1.. 19904 
Gentamicin 92 84.0 GermaQY Abb.19926 
38.4 Greece Sofianu. et al.. 19897 
Imipenem 	 100 93.5 Germany Abb.19926 
91 Germany Ansorg. et al.. 19904 
99.5 Greece Sofianu. et al.. 19897 
laboratory investigations. On the other hand, tolerance is 
only detected if actual MICs and MBCs are measured. 
Thus, an antibiotic such as azlocillin seems to be active 
against Ps. aeruginosa (Figure I), but in practice, many 
number of strains are actually tolerant to it (Figure 2). 
This is important in patients who require bactericidal 
drugs. 
Multiple Drug Resistance 
All three isolates which were resistant to ceftazidime 
showed cross resistance with ceftriaxone. However, four 
MDR isolates were sensitive to ceftriaxone and resistant 
to unrelated agents. This is important since only 47% of 
the isolates were sensitive to ceftriaxone. Thus, there is 
still a place for the use of ceftriaxone as an 
antipseudomonal agent even though more than 50% of 
isolates are resistant. 
Conclusions 
Ps. aeruginosa is one of the most important pathogens 
in hospitals, accounting for 11 % of all hospital acquired 
infections, according to the National Nosocomial 
Infections Surveillance System, 19891. Therefore, its 
resistance to a number of antimicrobial agents poses 
problems in the empiric selection of an appropriate drug 
for the treatment of infections caused by this organism. 
According to the results obtained, ceftazidime and 
gentamicin should be the empirical first line drugs to use 
Table 3. Health Service cost (Lm) of parenteral therapy 
Antibiotic Dose/phial Cost/phial Dose Regimen Cost for 
7 days 
Azlocillin 2.0g 1.94 2.0g t.d.s. 40.74 
Aztreonam 500mg 1.62 LOg t.d.s. 68.04 
Ceftazidime l.Og 2.90 l.Og t.d.s. 60.90 
Ceftriaxone 2.0g 10.00 2.0g b.d. 140.00 
Ciprofloxacin 200mg 8.77 200mg b.d. 122.78 
Gentamicin 40mg/ml 0.62 80mg t.d.s. 13.02 
Imipenem 500mg 8.40 500mg t.d.s. 176.40 
against Ps. aeruginosa infections since these two 
antibiotics are the only ones with a percentage 
sensitivity greater than 90. The second line agent 
imipenem should be reserved for strains resistant to 
first line agents, especially those resistant to both 
gentamicin and ceftazidime. 
When choosing the right antibiotic the price factor 
should be taken into account. Table 3 shows the 
approximate cost of treatment for a week with the 
seven antibiotics tested in this study. From this table 
one can see that gentamicin is the cheapest antibiotic 
whereas imipenem is the most expensive. This may be 
one reason why gentamicin is used as a first line agent 
even though it has a number of potential side effects 
and precautions for use, whereas, the safer antibiotic 
imipenem is classified as a second line agent. However, 
the most interesting finding was obtained by 
comparing resistance levels to ciprofloxacin in Malta 
with two studies carried out in Germany. In Malta only 
79% of the isolates were sensitive to ciprofloxacin as 
opposed to 90% in both German studies. This suggests 
the overuse or misuse of ciprofloxacin in Malta. It is 
likely to happen with any antibiotic which can be given 
by the oral route. In such a case, as with ciprofloxacin, 
there can be overuse of the antibiotic both in hospital 
and especially in community practice. A study of the 
development of resistance by Ps. aeruginosa during 
therapy with ciprofloxacin was published in 19898. 
This is even more alarming when considering that 
ciprofloxacin can induce low level resistance to 
structurally unrelated antibiotics in Ps. aeruginosa and 
methicillin resistant Staphylococcus aureus9. 
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